



CurvaFix Completes Treatment of First US Patient in RESTORE Clinical Study

Company Expands Executive Team; Announces Chief Commercial Officer

BELLEVUE, Wash., Oct. 8, 2020 – [CurvaFix, Inc.](#), a developer of medical devices to repair fractures in curved bones, announced today that it has enrolled and treated its first US patient in the RESTORE Clinical Study, a safety and technical feasibility evaluation of the CurvaFix® Intramedullary [Rodscrew](#) for fixation of pelvic and acetabular fractures. The patient, who suffered from a high-impact pelvic fracture due to an auto accident, was treated by Surgeon Investigator Dr. Joshua Gary of McGovern Medical School at The University of Texas Health Science Center at Houston.

“The patient had a volume expanding injury of the pelvic ring with disruption of the pubic symphysis and a complete dislocation of the left sacroiliac joint,” according to Dr. Gary, an associate professor in the [Department of Orthopedic Surgery](#). “He tolerated the surgery very well. I implanted a rodscrew inside the bone across the sacrum, then locked the rodscrew, converting it from flexible to rigid, enabling it to help maintain reduction of the sacroiliac dislocation during healing. It’s helpful to have the option to use a strong implant that can accommodate to a bony pathway that may not be linear.”

The company also announced that [Bart Balkman](#) has joined CurvaFix as chief commercial officer (CCO). The new addition comes as the company continues to expand the RESTORE clinical study to clinical sites in the U.S. and prepare for commercialization.

Mr. Balkman brings over 30 years of expertise in the medical device industry. Prior to joining CurvaFix, he served as CCO for Shape Memory Medical. Prior to this, he was vice president of sales for NuVasive Specialized Orthopedics, a position he assumed upon the purchase of Ellipse Technologies, where he was vice president of sales and marketing.

“We are thrilled to have Bart join our growing executive team as we expand our commercial operations throughout the U.S., and we value his expertise in driving adoption of unique technologies that serve an unmet need,” said [Steve Dimmer](#), chief executive officer. “During his tenure at Ellipse, Bart led commercialization of the PRECICE Intramedullary Limb Lengthening device, developed the worldwide distribution strategy and grew revenue from zero to over \$24 million.”

The CurvaFix Rodscrew System received [510\(k\) clearance](#) from the U.S. Food and Drug Administration (FDA) in the first half of 2019. The company is in the process of expanding the RESTORE Study to U.S. sites before the end of this year. The RESTORE Study is focused on gathering clinical evidence supporting the Rodscrew System’s potential benefits for [pelvic fracture](#) patients in advance of the company’s commercial launch.

About CurvaFix, Inc.

[CurvaFix, Inc.](#) is a privately held medical device company headquartered in Bellevue, Wash. The idea for the company germinated when the former division head of orthopedic trauma at the University of British Columbia, Clinical Professor Emeritus, Robert Meek, M.D., FRCSC, believed there was a better way to repair pelvic fractures. Today, CurvaFix is developing implantable products to improve fracture repair in curved bones. The company’s first product is the CurvaFix Rodscrew.

###

Media Contact:

Lorraine Marshall Wright
Lmwright@curvafix.com

CurvaFix is a trademark of CurvaFix, Inc., registered in the U.S.

1000 124th Ave NE
Suite 100
Bellevue, WA 98005
curvafix.com
+1.425.276.8800